MACH7 TECHNOLOGIES LIMITED — Investor Presentation 2024

May 12, 2024

ASX Announcement

13 May 2024

==> picture [104 x 26] intentionally omitted <==

Mach7 Investor Roadshow Presentation

Mach7 Technologies Limited (“M7T” or “the Company”) (ASX:M7T), a company specialising in innovative imaging software solutions, today provides the attached presentation ahead of an investor roadshow by the CEO Mike Lampron in Sydney and Melbourne this week.

Released on authority of the Board by:

Mike Lampron Managing Director and Chief Executive Officer

For more information, contact: Investor Relations Françoise Dixon +61 (0) 412 292 977 ir@mach7t.com

About Mach7 Technologies:

Mach7 Technologies (ASX:M7T), founded in 2007, is a medical imaging software company that enables exceptional patient care by empowering healthcare providers to make better informed decisions. Mach7’s Enterprise Imaging Solution comprises Enterprise Data Management, Enterprise Diagnostic Viewing and Departmental Workflow applications. Mach7’s Enterprise Data Management solution, consisting of a powerful Vendor Neutral Archive (VNA) and data administration tools, allows for the fast storage, access, retrieval and viewing of images across a healthcare network with connectivity to the Cloud. Mach7’s eUnity Enterprise Diagnostic Viewing technology is a zero-footprint, FDA-approved, image viewing solution that makes images accessible on any workstation. This, together with Mach7’s Departmental Workflow applications, offers healthcare professionals consolidated access to all patient images and data, ensuring radiologists and clinical staff have timely access to the right information to diagnose and treat patients. Uniquely, the Company gives customers the independence to deploy its solutions either on a component basis or in a unified comprehensive platform. With more than 165 customers across 15 countries, Mach7 has built a global network of customers ranging from expansive Integrated Delivery Networks, National Health Systems, medical research facilities, and large academic medical institutions to regional community hospitals, private radiology practices, and independent provider groups. Visit Mach7t.com.

Mach7 Technologies Limited (ASX:M7T) ABN: 26 007 817 192 Registered Office: Level 4, 96 – 100 Albert Road, South Melbourne, VIC 3205 T: 03 9692 7222 www.mach7t.com

==> picture [960 x 63] intentionally omitted <==

Investor Roadshow Presentation

May 2024

approved by the Board

1

1

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Our Business
----- End of picture text -----

==> picture [495 x 417] intentionally omitted <==

Our Purpose

To enable exceptional patient care by empowering healthcare providers to make more informed decisions.

Our Offering Innovative data storage, management and image viewing solutions for the healthcare enterprise.

2

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Our Value Proposition
----- End of picture text -----

Global Company with a Personal Touch

Lasting Technology Built for the Entire Enterprise

==> picture [58 x 57] intentionally omitted <==

==> picture [58 x 58] intentionally omitted <==

A future-proof solution built on a modern technology stack that allows customers to grow, adapt and innovate. Personalised customer service and support to ensure product stability, optimal performance and user satisfaction.

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

A software-only solution designed for the whole healthcare organisation.

A highly performant Enterprise Imaging Platform with robust interoperability and scalability to adapt to changing needs.

==> picture [58 x 58] intentionally omitted <==

==> picture [58 x 57] intentionally omitted <==

==> picture [58 x 58] intentionally omitted <==

Unique Deployment Flexibility

Vendor neutral solutions give independence; modular products allow select deployments. Capable of being used on existing IT infrastructures to leverage existing investments. Deploy on premise or in the cloud with integration to the latest technology platforms.

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 58] intentionally omitted <==

==> picture [58 x 58] intentionally omitted <==

A best of breed single universal viewing and data management platform to unify patient records. Support for telemedicine, teleradiology and telemammography workflows.

A secure solution designed to incorporate the latest advanced applications including AI algorithms, analytics and business intelligence tools.

3

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Our Solution – Enterprise Imaging Platform
----- End of picture text -----

Enterprise Data Management

Enterprise Diagnostic Viewing

Workflow Orchestration

Vendor Neutral Archive

eUnity Enterprise Diagnostic Viewer

Communication Workflow Engine

• ✓ Consolidate ALL images across the enterprise

• ✓ Allows customers to take control of their data

• ✓ Leverage existing IT infrastructure

• ✓ Store in native format or wrap in DICOM

• ✓ On-premise or via Cloud infrastructure

• ✓ Zero footprint HTML-5 viewer; 100% fidelity

• ✓ Virtual aggregation of imaging data across the enterprise

• ✓ 3D/MIP/MPR/ Mammography /Pet CT

• ✓ Image enable the EMR

• ✓ Image enablement for downtime PACS solution

• ✓ Data Normalisation through Dicom Tag Morphing

• ✓ Dicom Routing for complex workflows

• ✓ Sophisticated AI Workflow Optimisation

• ✓ Data anonymisation

• ✓ Image lifecycle management

• ✓ HL7 and clinical event-based rules engine

• ✓ Research and AI test platform

4

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Our Global Organisation
----- End of picture text -----

==> picture [889 x 395] intentionally omitted <==

----- Start of picture text -----

GEOGRAPHY
FUNCTION
Canada
28 Executive
& Admin
27 Engineering
34
USA
Head count
68
108
March 2024
Australia
2 Services
&
Singapore Sales &
Support
10 Marketing
34
13
----- End of picture text -----

5

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Our Highlights – As at 31 March 2024
----- End of picture text -----

==> picture [53 x 52] intentionally omitted <==

Record Sales Orders (TCV)[1 ] YTD FY24 A$56.9M Q3 FY24: A$7.4M

==> picture [204 x 185] intentionally omitted <==

----- Start of picture text -----

CARR [2]
A$28.2M
+5% on A$26.8M
at 31 Dec 2023
----- End of picture text -----

==> picture [53 x 53] intentionally omitted <==

==> picture [38 x 12] intentionally omitted <==

----- Start of picture text -----

ARR [3]
----- End of picture text -----

==> picture [126 x 46] intentionally omitted <==

----- Start of picture text -----

A$22.3M run rate
+20% on A$18.6M
at 31 Dec 2023
----- End of picture text -----

==> picture [52 x 53] intentionally omitted <==

==> picture [53 x 53] intentionally omitted <==

==> picture [52 x 53] intentionally omitted <==

New contracts, strong renewal program VHA, DIA, HAHK, Sentara, Penn State Health

Strong financial position with no debt Cash: A$24.8M +9% on A$22.7M at 31 Dec 2023

Renewed Board Refreshed Strategy Innovation focus Customer centric

6

1. TCV – Total Contract Value; 2. CARR: Contacted Annual Recurring Revenue; 3. ARR: Annual Recurring Revenue

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Our Momentum - CARR Leading Indicator of Future Recurring Revenue
----- End of picture text -----

Acceleration in subscription transition to drive future ARR growth

==> picture [426 x 313] intentionally omitted <==

----- Start of picture text -----

Sales Order Composition (TCV)
A$M
50
45
40
35
30
25
20
15
10
5
-
FY21 FY22 FY23 YTD FY24
Subscription / Support & Maintenance Capital Software Professional Services
----- End of picture text -----

==> picture [426 x 313] intentionally omitted <==

----- Start of picture text -----

CARR is Leading Indicator of ARR
A$M
30
A$5.9M
25
backlog
20
15
10
5
0
1H22 2H22 1H23 2H23 1H24 3Q24
ARR CARR
----- End of picture text -----

TCV: Total Contract Value;

ARR Run Rate: revenue earned from subscription and maintenance and support fees at the end of March/June/December, annualised; CARR: ARR Run Rate + annual subscription and maintenance and support fees where FPU or renewal date is yet to occur;. FPU: First Productive Use

7

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Our Strategy
----- End of picture text -----

Our Business Objectives

• Provide solutions that will compete at the enterprise level in selected market segments; focused on value-based solutions

• Grow recurring revenue, stay grounded in our purpose, and protect our ability to expand into new future revenue streams for profitable growth

• Drive financial KPIs with an eye to profitability

• Leverage our capability to innovate and create a pathway to investment

• Invest in our people, processes and products to further differentiate ourselves from our competitors

Our Product Focus

Product innovation focusing on:

• Cloud enablement (cloud adoption, migration, implementation)

• Service, supportability

• Interoperability

Our Company DNA

Culture of customer intimacy:

• Make our company more customer-centric

• Create an amazing customer support system

• Add extra value for our key customers

8

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

A Transformational Year to Date
----- End of picture text -----

Positioning Mach7 for long-term growth

==> picture [598 x 372] intentionally omitted <==

----- Start of picture text -----

1 Record sales orders of A$56.9M for the nine months to 31 March 2024
Successful completion of large renewal program creating foundational book of
2
business for medium term
3 Strong growth delivers record results for CARR and ARR
35%
Acceleration in subscription transition to result in high quality recurring revenue
4
providing greater earnings reliability
5 Strong financial position with no debt and on track to be cashflow positive in FY24
6 Renewed board; refreshed strategy
----- End of picture text -----

==> picture [271 x 384] intentionally omitted <==

----- Start of picture text -----

58%
32%
32%
10%
10%
58%
58%
----- End of picture text -----

9

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Outlook
----- End of picture text -----

	Fragmentation		Complex		Product			Sales pipeline
	opportunities		opportunities		Innovation			opportunities
•	Fragmented imaging	•	More complex reading	•	Invest in product		•	Following successful
	market with legacy		environments and remote		innovation to reflect a			completion of largest
	modality vendors losing		workforces becoming the		customer-centric			renewal plan in Mach7’s
	market share.		norm.		mindset and to			history, focus on net
•	Dynamics continuing to	•	Enterprise imaging		increase the scalability			new opportunities in
	skew toward ambulatory		strategies require		of the business.			FY25.
	from acute care settings.		innovation and	•	Focus on investment
•	Opportunities created for		interoperability to give		in people, process and
	Mach7’s enterprise		hospital networks and		tools that enable our		FY24 expectations
	imaging products which serve both ambulatory and acute markets.		private groups a simplified image management and diagnostic viewing		customers to achieve our purpose of enabling exceptional patient care.		• • •	Sales orders >A$60M Revenue of A$27M-$30M Opex growth < 15%
			solution from any				•	Cashflow positive in FY24
			location.

10

==> picture [211 x 52] intentionally omitted <==

==> picture [491 x 27] intentionally omitted <==

Contact Us

Investor Relations, Mach7 Françoise Dixon +61 (0) 412 292 977 ir@mach7t.com

Registered Office: Level 4 | 100 Albert Road, South Melbourne, VIC

This document was authorised for release to the ASX by Mike Lampron, Managing Director and Chief Executive Officer

Mach7 Technologies

11

Disclaimer “forward looking” statements

==> picture [960 x 23] intentionally omitted <==

Summary of information: This presentation contains general and background information about Mach7 Technologies Limited (“M7T”) activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision. This presentation is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or under any other law. The presentation does not purport to contain all the information that a prospective investor may require in assessing a possible investment in M7T nor does it contain all the information which would be required in a prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). The information provided is in summary form, has not been independently verified, and should not be considered to be comprehensive or complete. It should be read solely in conjunction with the oral briefing provided by M7T and all other documents provided to you by M7T. The information in this presentation remains subject to change without notice. M7T is not responsible for providing updated information and assumes no responsibility to do so.

Not financial product advice: This financial information provided in this presentation is for information purposes only. The information contained in this presentation is of a general nature only and is not a financial product, investment advice or a recommendation to acquire M7T securities and has been prepared without taking into account the objectives, financial situation or needs of any person or entity. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. M7T is not licensed to provide financial product advice in respect of its securities or and other financial products. Cooling off rights do not apply to the acquisition of M7T securities. M7T assumes that the recipient is capable of making its own independent assessment, without reliance on this document, of the information and potential investment and will conduct its own investigation.

Disclaimer: M7T and its related bodies corporate and each of their respective directors, agents, officers, employees and advisors expressly disclaim, to the maximum extent permitted by the law, all abilities (however, caused, including negligence) in respect of, make no representations regarding, and take no responsibility for, any part of this presentation and make no representation or warranty as to the currency, accuracy, reliability or completeness of any information, statements, opinions, conclusions or representations contained in this presentation. In particular, this presentation does not constitute, and shall not be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of M7T.

Future performance: This presentation contains certain forward-looking statements and opinions. The forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forwardlooking statements, including projections, forecasts and estimates, are provided as a general guide only and should not be relied on as an indication or guarantee of future performance and involve known and unknown risks, uncertainties and other factors, many of which are outside the control of M7T. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast.

Risks: An investment in M7T securities is subject to investment and other known and unknown risks, some of which are beyond the control of M7T. You should have regard to the ‘Key Risks’ section of this presentation which outlines some of these risks.

Not an offer: This presentation is not, and should not be considered as, an offer or an invitation to acquire securities in M7T or any other financial products and neither this document nor any of its contents will form the basis of any contract or commitment. This presentation is not a prospectus. Offers of securities in M7T will only be made in places which, or to persons to whom it would be lawful to make such offers. This presentation must not be disclosed to any other party and does not carry any right of publication. Neither this presentation nor any of its contents may be reproduced or used for any other purpose without the prior written consent of M7T.

No distribution in the US: This presentation is not an offer of securities for sale in the United States. Any securities to be issued by M7T have not been and will not be registered under the US Securities Act of 1933, as amended (the “US Securities Act”) and may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act. No public offer of the securities is being made in the United States and the information contained herein does not constitute an offer of securities for sale in the United States. This presentation is not for distribution directly or indirectly in or into the United States or to US persons.

Monetary values: Unless otherwise stated, all dollar values are in Australian dollars (AUD$). The information in this presentation remains subject to change without notice.

Sophisticated and professional investor: By attending this presentation, you present and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document as defined in the Corporation Act 2001 (Cth) (“Corporation Act”)) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are in the United States, you are a qualified institutional buyer (as defined under Rule 144A Under the U.S. Securities Act; (iii) if you are outside Australia and the United States, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this presentation and any copies and do not provide this presentation to any other person.

No distribution: Distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable security laws.

12